ION expands ETF trading capabilities with Tradeweb integration
Cathie Wood's ARK ETFs have made their latest round of daily trades for Tuesday, September 9th, 2025, with a mix of significant buys and sells that may indicate strategic shifts in their portfolio. Leading the day's activity, ARK's ARKG fund purchased 157,413 shares of Prime Medicine Inc (NASDAQ:PRME), with a total dollar value of approximately $612,336. This acquisition suggests a burgeoning interest in the biotech sector, as ARK continues to bolster its position in innovative healthcare companies.
Simultaneously, ARK executed a considerable sell-off of Tempus AI Inc (PRE-REINCORPORATION) (TEM), divesting a total of 25,936 shares across its ARKK and ARKG ETFs, amounting to a total dollar value of $2,080,585. This move comes as ARK appears to be reducing exposure to certain tech sectors, possibly reallocating funds to more promising ventures.
Another noteworthy buy for ARK was Twist Bioscience Corp (NASDAQ:TWST), with a combined purchase of 47,732 shares through both ARKK and ARKG ETFs. The total value of this transaction reached $1,252,965, signaling a strong vote of confidence in the synthetic biology company.
Looking at the recent trading patterns, ARK has shown a trend of increasing its holdings in Bitmine Immersion Technologies Inc (BMNR) over the past week, with substantial buys recorded on both Monday and the previous Saturday. Conversely, there has been a consistent offloading of shares in companies like Robinhood Markets Inc (NASDAQ:HOOD) and Teradyne Inc (NASDAQ:TER), indicating a possible strategic shift away from these stocks.
The ARK ETFs are known for their focus on disruptive innovation, and these daily trades provide insight into where Cathie Wood and her team see potential for significant growth and where they are choosing to cut their losses. Investors and market watchers alike will be keen to see how these recent moves play out in the ever-evolving landscape of the stock market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.